Melanie Märklin

2.2k total citations
49 papers, 686 citations indexed

About

Melanie Märklin is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Melanie Märklin has authored 49 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Immunology, 22 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Melanie Märklin's work include CAR-T cell therapy research (19 papers), Immune Cell Function and Interaction (18 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Melanie Märklin is often cited by papers focused on CAR-T cell therapy research (19 papers), Immune Cell Function and Interaction (18 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Melanie Märklin collaborates with scholars based in Germany, United States and Australia. Melanie Märklin's co-authors include Helmut R. Salih, Jonas S. Heitmann, Clemens Hinterleitner, Gundram Jung, Hans‐Georg Kopp, Hans‐Georg Rammensee, Juliane S. Walz, Joseph Kauer, Ilona Hagelstein and Malte Roerden and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Melanie Märklin

46 papers receiving 681 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melanie Märklin Germany 13 364 295 229 100 98 49 686
Jonas S. Heitmann Germany 14 314 0.9× 303 1.0× 201 0.9× 98 1.0× 112 1.1× 71 638
R. Handgretinger Germany 15 226 0.6× 222 0.8× 228 1.0× 109 1.1× 65 0.7× 33 718
Cecilia Muñoz‐Calleja Spain 15 307 0.8× 286 1.0× 199 0.9× 111 1.1× 29 0.3× 41 696
Joy Hsu United States 8 731 2.0× 581 2.0× 214 0.9× 65 0.7× 33 0.3× 16 1.0k
Keith M. Hamel United States 14 620 1.7× 197 0.7× 176 0.8× 64 0.6× 27 0.3× 18 922
Arnika Kathleen Wagner Sweden 13 337 0.9× 236 0.8× 239 1.0× 122 1.2× 24 0.2× 43 688
Haizhou Xing China 11 180 0.5× 208 0.7× 192 0.8× 162 1.6× 22 0.2× 31 561
Patrick Schlegel Germany 17 498 1.4× 529 1.8× 200 0.9× 329 3.3× 48 0.5× 44 1.1k
Chiara Gentilini Germany 14 605 1.7× 396 1.3× 177 0.8× 252 2.5× 22 0.2× 24 932
Arcadi Cipponi Italy 10 495 1.4× 476 1.6× 156 0.7× 127 1.3× 20 0.2× 14 783

Countries citing papers authored by Melanie Märklin

Since Specialization
Citations

This map shows the geographic impact of Melanie Märklin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Märklin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Märklin more than expected).

Fields of papers citing papers by Melanie Märklin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Märklin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Märklin. The network helps show where Melanie Märklin may publish in the future.

Co-authorship network of co-authors of Melanie Märklin

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Märklin. A scholar is included among the top collaborators of Melanie Märklin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Märklin. Melanie Märklin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zekri, Latifa, Ilona Hagelstein, Melanie Märklin, et al.. (2024). Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies. Science Translational Medicine. 16(737). eadh1988–eadh1988. 6 indexed citations
2.
Hagelstein, Ilona, André Koch, Jonas S. Heitmann, et al.. (2024). Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome. International Journal of Molecular Sciences. 25(7). 4126–4126. 6 indexed citations
3.
Schairer, Rebekka, Hildegard Keppeler, Hannes Schmid, et al.. (2024). PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. Journal for ImmunoTherapy of Cancer. 12(1). e007829–e007829. 7 indexed citations
4.
Hagelstein, Ilona, et al.. (2024). The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas. Frontiers in Immunology. 15. 1391954–1391954. 4 indexed citations
5.
Märklin, Melanie, et al.. (2023). Crosstalk between NFAT and NFκB Signaling Regulates NK Cell Immunosurveillance. Blood. 142(Supplement 1). 1183–1183.
6.
Hagelstein, Ilona, Tobias Engler, André Koch, et al.. (2023). Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer. International Journal of Molecular Sciences. 24(17). 13156–13156. 5 indexed citations
7.
Heitmann, Jonas S., Richard F. Schlenk, Daniela Dörfel, et al.. (2023). Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. Journal of Hematology & Oncology. 16(1). 96–96. 12 indexed citations
8.
Marconato, Maddalena, Joseph Kauer, Helmut R. Salih, Melanie Märklin, & Jonas S. Heitmann. (2022). Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia. Scientific Reports. 12(1). 15856–15856. 7 indexed citations
9.
Hagelstein, Ilona, Clemens Hinterleitner, Melanie Märklin, et al.. (2022). B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma. Frontiers in Immunology. 13. 1002898–1002898. 13 indexed citations
10.
Kauer, Joseph, Melanie Märklin, Clemens Hinterleitner, et al.. (2022). BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of Cancer Research and Clinical Oncology. 148(10). 2759–2771. 2 indexed citations
11.
Märklin, Melanie, Clemens Hinterleitner, Claudia Tandler, et al.. (2022). Identification of CD105 (endoglin) as novel risk marker in CLL. Annals of Hematology. 101(4). 773–780. 3 indexed citations
12.
Bilich, Tatjana, Annika Nelde, Jonas S. Heitmann, et al.. (2021). T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science Translational Medicine. 13(590). 92 indexed citations
13.
Märklin, Melanie, et al.. (2021). DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis. Scientific Reports. 11(1). 18012–18012. 11 indexed citations
14.
Hagelstein, Ilona, Martina S. Lutz, Jonas S. Heitmann, et al.. (2021). Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas. Frontiers in Immunology. 12. 653081–653081. 10 indexed citations
15.
Märklin, Melanie, Claudia Tandler, Jonas S. Heitmann, et al.. (2020). Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia. Frontiers in Immunology. 11. 1995–1995. 4 indexed citations
16.
Kauer, Joseph, Claudia Tandler, Clemens Hinterleitner, et al.. (2019). CD105 (Endoglin) as negative prognostic factor in AML. Scientific Reports. 9(1). 18337–18337. 21 indexed citations
17.
Märklin, Melanie, Ilona Hagelstein, Kathrin Rothfelder, et al.. (2019). Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia. Journal for ImmunoTherapy of Cancer. 7(1). 143–143. 35 indexed citations
18.
Märklin, Melanie, Jonas S. Heitmann, Michael Haap, et al.. (2018). A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia. Journal of Visualized Experiments. 3 indexed citations
19.
Märklin, Melanie, Jonas S. Heitmann, Michael Gutknecht, et al.. (2017). NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. Nature Communications. 8(1). 755–755. 30 indexed citations
20.
Bugl, Stefanie, Stefan Wirths, Markus P. Radsak, et al.. (2012). Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood. 121(5). 723–733. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonas S. Heitmann Breakdown of academic impact, for papers by R. Handgretinger Breakdown of academic impact, for papers by Cecilia Muñoz‐Calleja Breakdown of academic impact, for papers by Joy Hsu Breakdown of academic impact, for papers by Keith M. Hamel Breakdown of academic impact, for papers by Arnika Kathleen Wagner Breakdown of academic impact, for papers by Haizhou Xing Breakdown of academic impact, for papers by Patrick Schlegel Breakdown of academic impact, for papers by Chiara Gentilini Breakdown of academic impact, for papers by Arcadi Cipponi
Rankless by CCL
2026